TrialEnoblituzumab Plus Retifanlimab or Tebotelimab in Head and Neck Cancer
Trial details
- Registry ID
- NCT04634825
- Phase
- Phase 2
Drug research
Enoblituzumab
Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.
Drug identity checked against registry records
Also recorded as MGA271
A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.
Included trials
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Enoblituzumab Plus Retifanlimab or Tebotelimab in Head and Neck CancerNCT04634825 | MacroGenics | Phase 2 | Terminated | 2022-07-29Actual |
Regulatory dates and decisions
| No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed. |